clinical trial · NCT04631211
Thrombosomes® in Bleeding Thrombocytopenic Patients Study
Cellphire Therapeutics, Inc.·phase2·terminated·n = 21
ThrombocytopeniaHematologic MalignancyBone Marrow AplasiaMyeloproliferative DisordersMyelodysplastic SyndromesPlatelet RefractorinessThrombosomesLiquid Stored Platelets (LSP)
brief summary
This prospective, multicenter, randomized, open-label, Phase 2, parallel, dose ranging, multidose trial will enroll patients into 3 Thrombosomes dose groups and 1 control liquid stored platelets (LSP) group in order to evaluate, in a dose-escalation manner, the safety, and impact on bleeding, and the preliminary effect on coagulation measures of increasing doses of allogeneic Thrombosomes in comparison to standard of care, LSP.
started
Mar 5, 2021
primary completion
Jan 7, 2022
completion
Jan 7, 2022
last updated
May 25, 2023
official title
A Prospective, Multicenter, Randomized, Open-Label Phase 2, Parallel, Dose Ranging Multidose Study of Thrombosomes® vs Liquid Stored Platelets (LSP) in Bleeding Thrombocytopenic Patients
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol